|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, histological examination revealed that the extent of pulmonary fibrosis was attenuated in PAI-1<sup>-/-</sup> mice compared with that in WT mice.
|
30214528 |
2018 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results of this study provide first evidence of the potential benefits of combined inhibition of CXCR4 and PAI-1 in the pulmonary treatment of PF.
|
29777878 |
2018 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) formed in the injured alveolar epithelium also contributes to pulmonary fibrosis in a manner that involves vitronectin binding.
|
29474926 |
2018 |
|
Pulmonary Fibrosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate the antifibrotic effect of PTX on radiation-induced lung fibrosis and its effect on modulation of PKA and PAI-1 expression as possible antifibrotic mechanisms.
|
28337441 |
2017 |
|
Pulmonary Fibrosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In vivo studies, using ATII cell-specific PAI-1 conditional knockout mouse model generated recently in this laboratory, further support the role of PAI-1 in the activation of p53-p21-Rb cell cycle repression pathway, ATII cell senescence, and lung fibrosis induced by bleomycin.
|
28722352 |
2017 |
|
Pulmonary Fibrosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our studies provide a potential therapeutic approach whereby fenofibrate-induced miR-301a/miR-454 expression can ameliorate PH and lung fibrosis by reduction in ET-1 and PAI-1 levels in SCD.
|
26460070 |
2015 |
|
Pulmonary Fibrosis
|
0.300 |
Therapeutic
|
disease |
RGD |
The present study was undertaken to examine the effects on pulmonary fibrosis of silencing PAI-1 expression with small interfering RNA (siRNA) and to assess the possible underlying mechanisms.
|
22659625 |
2012 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
We show that CSP, an intervention targeting this pathway, protects the lung epithelium from apoptosis and prevents PF in BLM-induced lung injury via uPA-mediated inhibition of p53 and PAI-1.
|
22140072 |
2012 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice.
|
21734232 |
2011 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Transforming growth factor-β1 (TGF-β1, a potent profibrotic cytokine) and plasminogen activator inhibitor 1 (PAI-1) play important roles in the development of pulmonary fibrosis.
|
22088447 |
2011 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The distribution of siRNA in the lung, the PAI-1 level in bronchoalveolar (BAL) fluid and the extent of fibrotic changes in the lung were evaluated following the intranasal administration of PAI-1-siRNA in a mouse model of bleomycin-induced pulmonary fibrosis.
|
20388759 |
2010 |
|
Pulmonary Fibrosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Some key signaling pathways have been identified with the aid of pharmacological inhibitors, involved in the up-regulation of PAI-1 in context with several diseases, including obesity, insulin resistance, diabetic nephropathy, glomulonephritis, and pulmonary fibrosis.
|
17896950 |
2007 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
RGD |
[Changes of coagulation and fibrinolysis system in bronchoalveolar lavage fluid in lung fibrosis].
|
16224526 |
2005 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The significant effect of uPA and PAI-1 on epithelial repair suggests a mechanism by which the plasminogen system may modulate pulmonary fibrosis.
|
15308506 |
2004 |
|
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Studies with animals have shown that inhibition of the plasminogen system by PAI-1 increases the generation of pulmonary fibrosis.
|
12765340 |
2003 |